Stueland Katherine

Stueland Katherine, chief executive officer of GeneDx Holdings (WGS), has been a consistent seller of company stock over the past year, with Form 4 filings showing 66 total transactions and no open-market purchases. Her aggregate sell value reached approximately $14.7 million, while acquisitions—all compensation-related grants and option exercises—totaled just under $300,000. The recent activity, spanning March through June 2026, shows a clear directional bias: 17 open-market sales with zero buys, clustered around option exercises that carry no dollar value and appear mechanical in nature. The most concentrated selling occurred on March 26, 2026, when Stueland executed five separate sales totaling roughly $2.96 million, alongside a zero-value option exercise. Additional significant sales took place on March 4 ($1.55 million combined), March 16 ($1.32 million), and June 16 ($638,000), with smaller dispositions scattered across March, April, and June. The only acquisition of note was a $299,926 grant on March 6, 2026, classified as compensation rather than a conviction purchase. Transaction sizes have ranged from modest amounts like the $1,154 sale on April 29 to eight-figure individual trades, though the overall pattern suggests systematic liquidation of exercised shares rather than opportunistic market timing.